// App-Quantinova.ai

69 : High baseline serum IL-6 identifies a subgroup of rheumatoid arthritis patients with rapid joint damage and clinical progression and predicts increased sarilumab treatment response

Researchers

Presenter

  • Anita Boyapati

Principal Investigators

  • Jrme Msihid

  • Sergio Schwartzman

  • Ernest Choy

  • Gerd R Burmester

  • Gordon Lam

  • Toshio Kimura

  • Jonathan Sadeh

  • Neil M H Graham

Medical Centers

  • Precision Medicine, Regeneron Pharmaceuticals, Inc., Tarrytown, NY

  • Biostatistics and Programming, Sanofi, Chilly-Mazarin, FRANCE

  • Division of Rheumatology, Hospital for Special Surgery, New York, NY

  • CREATE Center, Cardiff University School of Medicine, Cardiff, UNITED KINGDOM

  • Department of Rheumatology and Clinical Immunology, Charite - Universitatsmedizin Berlin, Berlin, Germany

  • Rheumatology, Atrium Health, Charlotte, NC

  • Medical Analytics, Medical Affairs, Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA

  • Immunology and Inflammation Franchise, Sanofi Genzyme, Bridgewater, NJ

  • Immunology and Inflammation, Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Locations

  • United States

  • France

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Interleukin 6

Drug/Treatment

  • Adalimumab

  • Sarilumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • NCT01061736

  • NCT02332590

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved